{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:06:16Z","timestamp":1779807976538,"version":"3.53.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangdong Raynovent Biotechnology Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40261-026-01556-w","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:58:50Z","timestamp":1777604330000},"page":"609-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Drug\u2013Drug Interaction of Leritrelvir in Healthy Chinese Volunteers: A Single-Arm, Open-Label, Dual-Cohort Study"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct06031454","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jiao","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Zhai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ka","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"2","key":"1556_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/v13020202","volume":"13","author":"A Sharma","year":"2021","unstructured":"Sharma A, Ahmad I, Lal S. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202.","journal-title":"Viruses"},{"issue":"6","key":"1556_CR2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s11596-023-2797-3","volume":"43","author":"N Xie","year":"2023","unstructured":"Xie N, Zhang W, Chen J, et al. Clinical characteristics, diagnosis, and therapeutics of COVID-19: a review. Curr Med Sci. 2023;43(6):1066\u201374.","journal-title":"Curr Med Sci."},{"issue":"6575","key":"1556_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"D Owen","year":"2021","unstructured":"Owen D, Allerton C, Anderson A, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586\u201393.","journal-title":"Science"},{"issue":"1","key":"1556_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1039\/D3MD00493G","volume":"15","author":"Y Janin","year":"2024","unstructured":"Janin Y. On the origins of SARS-CoV-2 main protease inhibitors. RSC Med Chem. 2024;15(1):81\u2013118.","journal-title":"RSC Med Chem"},{"issue":"3","key":"1556_CR5","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342\u20139.","journal-title":"Clin Infect Dis"},{"key":"1556_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114367","volume":"162","author":"S Hashemian","year":"2023","unstructured":"Hashemian S, Sheida A, Taghizadieh M, et al. Paxlovid (nirmatrelvir\/ritonavir): a new approach to Covid-19 therapy. Biomed Pharmacother. 2023;162:114367.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1556_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen X, Huang X, Ma Q, et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol. 2024;9(4):1075\u201388.","journal-title":"Nat Microbiol"},{"key":"1556_CR8","volume":"63","author":"B Wang","year":"2023","unstructured":"Wang B, Li H, Cai M, et al. Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial. E Clin Med. 2023;63:102189.","journal-title":"E Clin Med"},{"issue":"1","key":"1556_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmi.2024.09.007","volume":"31","author":"P Ye","year":"2025","unstructured":"Ye P, Yao B, Yang Y, et al. Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial. Clin Microbiol Infect. 2025;31(1):101\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"1556_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/17425255.2023.2288681","volume":"19","author":"A Cuomo","year":"2023","unstructured":"Cuomo A, Barill\u00e0 G, Serafini G, et al. Drug-drug interactions between COVID-19 therapeutics and psychotropic medications. Expert Opin Drug Metab Toxicol. 2023;19(12):925\u201336.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"1556_CR11","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/jac\/dkaa340","volume":"75","author":"D Hodge","year":"2020","unstructured":"Hodge D, Marra F, Marzolini C, et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother. 2020;75(12):3417\u201324.","journal-title":"J Antimicrob Chemother"},{"key":"1556_CR12","unstructured":"National Medical Products Administration (NMPA). Technical guidelines for drug interaction studies (trial). https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=e0293bfd34a7c44a93382776199101bb. Accessed 23 Dec 2024."},{"key":"1556_CR13","unstructured":"The World Medical Association (WMA). Declaration of Helsinki. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 23 Dec 2024."},{"key":"1556_CR14","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Health-related Research involving Humans. Council for International Organizations of Medical Sciences, 2016. https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf. Accessed 23 Dec 2024."},{"key":"1556_CR15","unstructured":"International Council for Harmonisation (ICH). Efficacy guidelines. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed 23 Dec 2024."},{"key":"1556_CR16","volume":"67","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Lin Z, Liang J, et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. E Clin Med. 2024;67:102359.","journal-title":"E Clin Med"},{"issue":"5","key":"1556_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","volume":"5","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shi L, Wang F. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1556_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.938552","volume":"13","author":"E Jeong","year":"2022","unstructured":"Jeong E, Nelson SD, Su Y, et al. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol. 2022;13:938552.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1556_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01450-24","volume":"69","author":"Y Hu","year":"2025","unstructured":"Hu Y, Li H, Wang K, et al. Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants. Antimicrob Agents Chemother. 2025;69(3):e0145024.","journal-title":"Antimicrob Agents Chemother"},{"key":"1556_CR20","unstructured":"International Council for Harmonisation (ICH). ICH guideline M12 on drug interaction studies. Step 2b, 2022. Accessed 23 Dec 2024."},{"issue":"7","key":"1556_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1124\/dmd.111.038067","volume":"39","author":"X Yang","year":"2011","unstructured":"Yang X, Yihong Z, Mike H, et al. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos. 2011;39(7):1139\u201348.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1556_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","volume":"21","author":"AJ Kapetas","year":"2019","unstructured":"Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A. Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction. AAPS J. 2019;21(5):78.","journal-title":"AAPS J"},{"issue":"4","key":"1556_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13318-023-00833-9","volume":"48","author":"S Bettonte","year":"2023","unstructured":"Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Management of drug interactions with inducers: onset and disappearance of induction on cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1 substrates. Eur J Drug Metab Pharmacokinet. 2023;48(4):353\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"1556_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, et al. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies. Clin Pharmacokinet. 2020;59(6):699\u2013714.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1556_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40268-016-0133-0","volume":"16","author":"NR Srinivas","year":"2016","unstructured":"Srinivas NR. Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs R&D. 2016;16(2):141\u20138.","journal-title":"Drugs R&D"},{"issue":"7","key":"1556_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1212\/01.wnl.0000267319.18123.d3","volume":"69","author":"A Cohen","year":"2007","unstructured":"Cohen A, Matharu M, Goadsby P. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007;69(7):668\u201375.","journal-title":"Neurology"},{"issue":"1","key":"1556_CR27","volume":"2","author":"J Alexandre","year":"2015","unstructured":"Alexandre J, Humbert X, Sassier M, et al. High-dose verapamil in episodic and chronic cluster headaches and cardiac adverse events: is it as safe as we think? Drug Saf. 2015;2(1):13.","journal-title":"Drug Saf"},{"issue":"1","key":"1556_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-252677","volume":"16","author":"O Haque","year":"2023","unstructured":"Haque O, Mahar S, Hussain S, et al. Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. BMJ Case Rep. 2023;16(1):e252677.","journal-title":"BMJ Case Rep"},{"key":"1556_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150341","volume":"14","author":"Y Tang","year":"2023","unstructured":"Tang Y, Li Y, Song T. Optimizing the use of nirmatrelvir\/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies. Front Immunol. 2023;14:1150341.","journal-title":"Front Immunol"},{"issue":"6","key":"1556_CR30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini C, Kuritzkes D, Marra F, et al. Recommendations for the management of drug\u2013drug interactions between the COVID \u201019 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112(6):1191\u2013200.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1556_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1556_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s11904-015-0277-5","volume":"12","author":"O El-Sherif","year":"2015","unstructured":"El-Sherif O, Back D. Drug interactions of Hepatitis C direct-acting antivirals in the HIV-infected person. Curr HIV\/AIDS Rep. 2015;12(3):336\u201343.","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01556-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:48:28Z","timestamp":1779806908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01556-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01556-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conception and design of the study: LD, ZX, KH, and HL. Analysis and interpretation of data: JP, JC, XD, HL, and KH. Drafting the article: JP, KH, ZX, and LY. Revising it critically for important intellectual content: JP, JC, XD, HL, RQ, SC, XL, QC, XL, DH, ML, WW, LY, YL, LD, ZX, and KH. All authors read and approved the final version and agree to be accountable for all aspects of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Hai-Jun Li and You-Yun Li are employees of Guangdong Raynovent Biotechnology Co., Ltd. The Second Affiliated Hospital of Guangzhou Medical University received funding from Guangdong Raynovent Biotechnology Co., Ltd. to conduct this study. Juan Chen, Xiao-Xiao Du, Ru-Zhai Qin, Si-Han Chen, Qi Cheng, Xiao-Mei Li, Dong-Xiang Huang, Lian Duan, Ming-Yan Li, Wen-Zheng Wu, Li-Ka Ye, Zhi-Hong Xie, and Ke Han are employees of The Second Affiliated Hospital of Guangzhou Medical University. Jiao Peng and Xian Liu were postgraduates at the time of the study; they declare no conflicts of interest that are directly relevant to the content of this study. Ming-Yan Li and Wen-Zheng Wu have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University (approval no. Y2023-39-01).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave their written informed consent for participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}